Soyasaponin II protects against acute liver failure through diminishing YB-1 phosphorylation and Nlrp3-inflammasome priming in mice

Autor: Shenhai Gong, Guiming Chen, Hongwei Zhou, Zhanguo Liu, Haihua Luo, Junhao Wang, Yong Jiang, Fangzhao Wang, Peng Chen, Teng Wang, Chenyang Huang, Qifan Zhang, Lei Li
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Lipopolysaccharide
Inflammasomes
Interleukin-1beta
Anti-Inflammatory Agents
Medicine (miscellaneous)
Priming (immunology)
Pharmacology
Protective Agents
Immunofluorescence
YB-1
Mice
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
soyasaponin II
NLR Family
Pyrin Domain-Containing 3 Protein

medicine
Animals
Humans
Oleanolic Acid
Pharmacology
Toxicology and Pharmaceutics (miscellaneous)

Messenger RNA
medicine.diagnostic_test
Chemistry
Macrophages
Binding protein
Inflammasome
Promoter
acute liver failure
Liver Failure
Acute

Saponins
Mice
Inbred C57BL

RAW 264.7 Cells
030104 developmental biology
Liver
Nlrp3-inflammasome
Phosphorylation
030211 gastroenterology & hepatology
Y-Box-Binding Protein 1
Transcription Factors
Research Paper
medicine.drug
Zdroj: Theranostics
ISSN: 1838-7640
Popis: Acute liver failure is characterized by the rapid development of liver dysfunction and remarkably high mortality. Accumulating evidence suggests that soyasaponin possesses potential anti-inflammatory activities. Here, we aimed to investigate the potential role of soyasaponin II in acute liver failure and establish the underlying mechanism. Methods: Lipopolysaccharide/D-galactosamine (LPS/GalN) was employed to induce acute liver failure. We applied liquid chromatography and mass spectrometry (LC/MS) to characterize the changes of soyasaponin II levels in the cecal content and liver. Transcriptomics and proteomics analysis were used to evaluate the functional molecule mediated by soyasaponin II in macrophages. Results: LPS/GalN administration markedly decreased fecal and hepatic soyasaponin II levels. Soyasaponin II treatment protected mice against LPS/GalN induced acute liver injury. Additionally, soyasaponin II markedly diminished Y-Box Binding Protein 1 (YB-1) phosphorylation and nuclear translocation, Nlrp3 inflammasome priming, and interleukin 1β (Il-1β) production in macrophages. Phosphorylated YB-1 could activate Nlrp3 mRNA transcription by binding the promoter region. Finally, immunofluorescence analysis showed elevated p-YB-1 nuclear translocation in macrophages of acute liver failure patients compared to controls. Conclusion: Our data shows that soyasaponin II which serves as a novel inhibitor for YB-1 phosphorylation and Nlrp3 inflammasome priming could protect mice against LPS/GalN induced acute liver failure.
Databáze: OpenAIRE